Atrial Septal Defect Market Report 2026

The atrial septal defect market size has grown strongly in recent years. It will grow from $4.46 billion in 2025 to $4.81 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to improved detection of congenital heart defects, increased availability of surgical correction techniques, expansion of pediatric cardiology services, growing clinical experience with device-based closures, wider access to diagnostic imaging technologies.

The atrial septal defect market size is expected to see strong growth in the next few years. It will grow to $6.26 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing adoption of hybrid closure techniques, rising focus on early intervention in adults, expansion of minimally invasive cardiac surgery capabilities, growing innovation in occluder device design, increasing demand for long-term follow-up care solutions. Major trends in the forecast period include increasing adoption of transcatheter closure devices, rising preference for minimally invasive repair procedures, growing use of advanced cardiac imaging techniques, expansion of pediatric and adult asd screening programs, enhanced focus on long-term patient outcomes.

The rising prevalence of congenital heart defects (CHD) is anticipated to drive the growth of the atrial septal defect market in the coming years. Congenital heart defects are structural abnormalities in the heart that are present from birth. The increasing prevalence of these defects reflects the growing number of individuals diagnosed with structural heart abnormalities since birth. Treatment for atrial septal defects helps manage congenital heart defects by correcting abnormal blood flow between the heart’s chambers, enhancing overall heart function, and reducing related complications. For example, in September 2025, according to the British Heart Foundation, a UK-based non-profit organization, there are 2.3 million people in the UK living with congenital heart disease. Additionally, congenital heart defects are identified in at least 1 in 150 births, which averages to 13 babies each day in the UK, with further diagnoses occurring later in life. Estimates indicate that up to 1-2 percent of the population may be affected. Consequently, the prevalence of congenital heart defects is expected to propel the atrial septal defect market.

Major companies operating in the arterial septal defect market are focusing on developing advanced devices and obtaining approval to expand their availability and applications. Device approval involves securing official authorization or certification for a device, usually from a regulatory authority, before it can be legally manufactured, marketed, or used in a particular market or for a specific purpose. For example, in March 2024, Occlutech GmbH, a Sweden-based specialist in minimally invasive cardiac devices, announced that the United States Food and Drug Administration (FDA) had approved the Occlutech ASD Occluder and Occlutech Pistol Pusher for the treatment of atrial septal defects (ASD). This approval represents an important milestone for the company, which has been striving to advance global healthcare. The Occlutech ASD Occluder is designed as a lifelong solution for patients with echocardiography-confirmed defects. It is a self-expanding nitinol device featuring two flexible discs that attach to both sides of the patient's atrial septum using the Occlutech Pistol Pusher. Following this approval, Occlutech will initiate commercialization in the US through an exclusive partnership with B. Braun Interventional Systems.

In August 2024, Occlutech, a Switzerland-based provider of minimally invasive structural heart devices, partnered with B. Braun Interventional Systems to enable the commercial implantation of the Occlutech ASD Occluder in leading U.S. centers. Through this collaboration, the companies aim to offer an effective, minimally invasive solution for closing atrial septal defects, leveraging Occlutech’s robust clinical data and B. Braun’s U.S. commercialization infrastructure. This partnership highlights the ASD device market’s focus on regulatory-driven commercial expansion and increased patient access. B. Braun Interventional Systems is a U.S.-based provider of interventional cardiovascular technologies.

Major companies operating in the atrial septal defect market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., Cook Medical, Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Lifetech Scientific Corporation, Venus Medtech Hangzhou Inc, Occlutech Holding AG, Osypka AG, Cardia Inc, Gore Medical, Pfm Medical AG, Balton Sp. z o.o., Meril Life Sciences, TTK Healthcare, Braile Biomedica, Shanghai Shape Memory Alloy.

North America was the largest region in the atrial septal defect market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atrial septal defect market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atrial septal defect market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the atrial septal defect market by increasing costs of imported occluder devices, catheters, imaging systems, and surgical instruments used in both transcatheter and surgical closure procedures. Cardiac centers in North America and Europe are most affected due to dependence on imported specialized devices, while Asia-Pacific faces cost challenges in expanding advanced intervention programs. These tariffs are contributing to higher treatment costs and procurement delays. However, they are also encouraging domestic medical device manufacturing, regional clinical innovation, and localized supply chains for congenital heart defect treatment technologies.

The atrial septal defect market research report is one of a series of new reports that provides atrial septal defect market statistics, including atrial septal defect industry global market size, regional shares, competitors with a atrial septal defect market share, detailed atrial septal defect market segments, market trends and opportunities, and any further data you may need to thrive in the atrial septal defect industry. This atrial septal defect market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An atrial septal defect (ASD) is a congenital heart condition marked by an abnormal opening in the septum, the wall that separates the heart’s two upper chambers (atria). This opening permits oxygen-rich blood from the left atrium to mix with oxygen-poor blood in the right atrium, potentially increasing blood flow to the lungs and, over time, leading to complications such as pulmonary hypertension and heart failure.

The primary treatment options for arterial septal defect include surgical closure, transcatheter closure, hybrid procedures, and medication therapy. Surgical closure involves repairing or sealing an abnormal opening or defect in the body, such as in the heart, through surgical intervention. Diagnostic techniques include chest X-rays, electrocardiograms, cardiac catheterization, transesophageal echocardiography, and pulse oximetry, supported by medical devices and pharmaceutical products. These diagnostic methods cater to both pediatric and adult patients in various end-user settings, such as hospitals, ambulatory surgical centers, cardiac clinics, and others.

The atrial septal defect (ASD) market consists of revenues earned by entities by provide services such as diagnosis and monitoring, medication management, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The atrial septal defect (ASD) market also includes sales of septal occluder devices, cardiac MRI systems, and anticoagulant medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.